Tianjin Pharmaceutical announced that its subsidiary Hubei Tianjin Pharmaceutical has received the drug registration certificate for Compound Electrolyte Injection approved and issued by the National Medical Products Administration. The drug specification is 500ml, and the registration classification is chemical drug category 4. It can be used as a source of water and electrolyte replenishment and as an alkalizing agent. In October 2024, Hubei Tianjin Pharmaceutical submitted the registration and marketing application, which was accepted. As of the announcement date, the research and development investment was approximately 3.2 million yuan.
Tianjin Tianyao Pharmaceuticals Co LtdSubsidiary obtains drug registration certificate for new product, expanding portfolio.
Directly receives registration certificate for Compound Electrolyte Injection.